{"id":390034,"date":"2021-05-05T00:00:00","date_gmt":"2021-05-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2021-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2021\/"},"modified":"2026-04-27T11:24:44","modified_gmt":"2026-04-27T11:24:44","slug":"unneim0017-2021-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2021-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2021\/","title":{"rendered":"Rheumatoid Arthritis | Unmet Need | TNF-Alpha Refractory | US\/EU | 2021"},"content":{"rendered":"<p>Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-\u03b1) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol Myers Squibb\u2019s Orencia, Roche\u2019s Actemra \/ RoActemra, Roche\u2019s Rituxan \/ MabThera). The launch of AbbVie\u2019s Rinvoq in the United States and Europe, along with Pfizer\u2019s Xeljanz in Europe and Eli Lilly \/ Incyte\u2019s Olumiant in both the United States and Europe, gives physicians more treatment options with a convenient route of administration (i.e., oral). However, recent safety data raise new concerns about JAK inhibitors, highlighting an unmet need for a lower risk of cardiovascular events or malignancy. Although the RA therapy market offers multiple efficacious and relatively safe agents, patients refractory to TNF-\u03b1 inhibitors have limited options, even with the recent entry of newer agents; therefore, substantial unmet need remains in the treatment of tumor necrosis factor inhibitor (TNFi)-refractory RA.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for TNFi-refractory RA?<\/li>\n<li>What drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for TNFi-refractory RA?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in TNFi-refractory RA?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug for TNFi-refractory RA?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European rheumatologists fielded in February 2021<\/p>\n<p><strong>Key companies: <\/strong>Amgen, Pfizer, Roche, Biogen, Bristol Myers Squibb, Eli Lilly, AbbVie<\/p>\n<p><strong>Key drugs:<\/strong> Enbrel, Rituxan \/ MabThera, Orencia, Actemra \/ RoActemra, Xeljanz, Olumiant, Rinvoq<\/p>\n<p>\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-390034","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390034\/revisions"}],"predecessor-version":[{"id":393159,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390034\/revisions\/393159"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}